EIP
VNDA icon

Easterly Investment Partners’s Vanda Pharmaceuticals VNDA Stock Holding History

Easterly Investment Partners’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-60,557
Closed -$411K – 210
2023
Q1 		$411K Buy
+60,557
New +$426K 0.04% 170

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Easterly Investment Partners's VNDA Position: Q2 2023 in Review

Easterly Investment Partners sold out of Vanda Pharmaceuticals (VNDA) in Q2 2023, closing a stake of 60,557 shares — an estimated $411K sold.

Easterly Investment Partners first reported a position in VNDA in Q1 2023 and held it in 1 quarter. The position peaked at $411K in Q1 2023. 188 funds tracked by Wall St. Rank hold VNDA as of Q2 2023.

  • Easterly Investment Partners reported no remaining Vanda Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Easterly Investment Partners sold 60,557 Vanda Pharmaceuticals shares in Q2 2023, an estimated $411K.
  • Easterly Investment Partners first reported a position in Vanda Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Easterly Investment Partners's Vanda Pharmaceuticals position peaked at $411K in Q1 2023.
  • 188 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2023.

Based on Easterly Investment Partners's 13F filing for Q2 2023, filed 13 Nov 2023.